Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of vernakalant and flecainide on atrial contractility in atrial fibrillation
2012-001898-90Phase 4Active
- Sponsor
- Maastricht University Medical Center+
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of vernakalant and flecainide in Atrial fibrillation (AFib) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Atrial contractility after conversion to sinus rhythm. Started May 2012; status: active.
02
Drugs
vernakalantflecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2012-001898-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001898-90.